TR200101085T2 - Kronik hepatit C enfeksiyonlu hastalarda algılanabilir HCV-RNA'nın yok edilmesi için birleşik ribavirin-interferon alfa tedavisi - Google Patents

Kronik hepatit C enfeksiyonlu hastalarda algılanabilir HCV-RNA'nın yok edilmesi için birleşik ribavirin-interferon alfa tedavisi

Info

Publication number
TR200101085T2
TR200101085T2 TR2001/01085T TR200101085T TR200101085T2 TR 200101085 T2 TR200101085 T2 TR 200101085T2 TR 2001/01085 T TR2001/01085 T TR 2001/01085T TR 200101085 T TR200101085 T TR 200101085T TR 200101085 T2 TR200101085 T2 TR 200101085T2
Authority
TR
Turkey
Prior art keywords
rna
infection
chronic hepatitis
elimination
patients
Prior art date
Application number
TR2001/01085T
Other languages
English (en)
Turkish (tr)
Inventor
K. Ganguly Ashit
Mccormick Jinping
G. Lovey Raymond
Bennett Frank
K. Saksena Anil
M. Girijavallabhan Viyyoor
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/348,534 external-priority patent/US6277830B1/en
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of TR200101085T2 publication Critical patent/TR200101085T2/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056Triazole or tetrazole radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
TR2001/01085T 1998-10-16 1999-10-14 Kronik hepatit C enfeksiyonlu hastalarda algılanabilir HCV-RNA'nın yok edilmesi için birleşik ribavirin-interferon alfa tedavisi TR200101085T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17405998A 1998-10-16 1998-10-16
US09/348,534 US6277830B1 (en) 1998-10-16 1999-07-07 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon

Publications (1)

Publication Number Publication Date
TR200101085T2 true TR200101085T2 (tr) 2001-08-21

Family

ID=26869824

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/01085T TR200101085T2 (tr) 1998-10-16 1999-10-14 Kronik hepatit C enfeksiyonlu hastalarda algılanabilir HCV-RNA'nın yok edilmesi için birleşik ribavirin-interferon alfa tedavisi

Country Status (20)

Country Link
EP (1) EP1121369B1 (https=)
JP (1) JP2002527522A (https=)
CN (1) CN1330658A (https=)
AT (1) ATE284408T1 (https=)
AU (1) AU762395B2 (https=)
BR (1) BR9915546A (https=)
CA (1) CA2346447C (https=)
CZ (1) CZ20011130A3 (https=)
DE (1) DE69922529T2 (https=)
ES (1) ES2229820T3 (https=)
HU (1) HUP0200447A2 (https=)
ID (1) ID29187A (https=)
IL (1) IL142423A0 (https=)
NO (1) NO20011789L (https=)
NZ (1) NZ510811A (https=)
PL (1) PL347268A1 (https=)
RU (1) RU2001113268A (https=)
SK (1) SK4742001A3 (https=)
TR (1) TR200101085T2 (https=)
WO (1) WO2000023454A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001081359A1 (en) * 2000-04-20 2001-11-01 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
RU2005133093A (ru) * 2003-03-28 2006-07-27 Фармассет, Инк. (Us) Соединения для лечения флавивирусных инфекций
JP2007501806A (ja) * 2003-08-13 2007-02-01 ハワード ジェイ. スミス アンド アソシエイツ ピーティーワイ エルティーディー ウィルス感染を治療する方法
US7410979B2 (en) 2003-11-19 2008-08-12 Rigel Pharmaceuticals, Inc. Synergistically effective combinations of dihaloacetamide compounds and interferon or ribavirin against HCV infections
CA2606106A1 (en) 2005-05-02 2007-03-08 Rigel Pharmaceuticals, Inc. Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses
EP2201953A4 (en) 2007-08-27 2011-08-03 Univ Nagoya Nat Univ Corp USE OF RIBAVIRIN IN BLOOD CLEANING DISORDERS
JPWO2009028575A1 (ja) 2007-08-27 2010-12-02 国立大学法人名古屋大学 血液凝固第vii因子プロモーターの活性化剤及びその利用
WO2011151667A1 (en) 2010-06-02 2011-12-08 Adbula Kurkayev Antiviral compositions
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
DE112012002748T5 (de) 2011-10-21 2014-07-31 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
SE1450131A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
JP2019532027A (ja) 2016-08-17 2019-11-07 ソルスティス バイオロジクス,リミティッド ポリヌクレオチド構築物
WO2019006455A1 (en) 2017-06-30 2019-01-03 Solstice Biologics, Ltd. AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF
CN107513055B (zh) * 2017-08-11 2018-06-22 广东昊邦医药健康有限责任公司 一种利巴韦林衍生化合物及其药物组合物
US20240325419A1 (en) 2022-05-05 2024-10-03 Abdula Kurkayev Pharmaceutical composition for restoring physiological processes and cells of organism

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1482736A (en) * 1974-03-18 1977-08-10 Icn Pharmaceuticals 1-(beta-d-ribofuranosyl)-1,2,4-triazole acid derivatives
US4544741A (en) * 1982-03-29 1985-10-01 Robins Roland K Azole dinucleotide compounds and methods for their production
US4925930A (en) * 1988-11-02 1990-05-15 Nucleic Acid Research Institute Synthesis and anti-leukemic activity of alkyl-1-(β-D-ribofuranosyl)[1,2,4]triazole-3-carboximidates
GB9307043D0 (en) * 1993-04-05 1993-05-26 Norsk Hydro As Chemical compounds
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
JP2001503767A (ja) * 1996-11-12 2001-03-21 メディヴィル・アクチボラグ ヌクレオシド

Also Published As

Publication number Publication date
AU762395B2 (en) 2003-06-26
ID29187A (id) 2001-08-09
CZ20011130A3 (cs) 2001-08-15
IL142423A0 (en) 2002-03-10
ES2229820T3 (es) 2005-04-16
JP2002527522A (ja) 2002-08-27
SK4742001A3 (en) 2001-11-06
NO20011789L (no) 2001-06-11
CA2346447A1 (en) 2000-04-27
DE69922529T2 (de) 2005-12-15
NZ510811A (en) 2003-06-30
DE69922529D1 (de) 2005-01-13
HUP0200447A2 (en) 2002-06-29
AU1197500A (en) 2000-05-08
WO2000023454A1 (en) 2000-04-27
CN1330658A (zh) 2002-01-09
RU2001113268A (ru) 2003-09-27
ATE284408T1 (de) 2004-12-15
EP1121369A1 (en) 2001-08-08
BR9915546A (pt) 2001-08-14
CA2346447C (en) 2006-01-31
PL347268A1 (en) 2002-03-25
NO20011789D0 (no) 2001-04-09
EP1121369B1 (en) 2004-12-08

Similar Documents

Publication Publication Date Title
TR200101085T2 (tr) Kronik hepatit C enfeksiyonlu hastalarda algılanabilir HCV-RNA'nın yok edilmesi için birleşik ribavirin-interferon alfa tedavisi
MY129244A (en) Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis c infection.
WO2000037110A3 (en) Ribavirin-pegylated interferon alfa induction hcv combination therapy
AR013497A1 (es) Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion de hepatitis c cronica
NZ309217A (en) Ribavirin and interferon alpha for the treatment of hepatitis C
MY124091A (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
HK1052878A1 (zh) 利巴传林-聚乙二醇化干扰素α:丙型肝炎病毒的联合治疗
AR021226A1 (es) Terapia combinatoria con ribavirina-interferon alfa para erradicar el hcv-rna detectable en aquellos pacientes que presentan infeccion porhepatitis c cronica
BR0009840A (pt) Terapia de combinação para hcv, contendo ribavirina em associação com antioxidantes
BR9913951A (pt) Tratamento de infecção de hepatite b com timosina alfa 1 em combinação com lamivudina e flamciclovir
IL154299A0 (en) Treatment of hepatitis c with thymosin, interferon and ribavirin
ECSP993178A (es) Terapia combinatoria con ribarvirina -interferon alfa para erradicar el hcv - rna detectable en aquellos pacientes que presentan infeccion por hepatitis c cronica
ECSP982669A (es) Terapia en combinacion para erradicar vhc -arn detectable en pacientes que padecen infeccion de hetatitis c cronica
BR0009642A (pt) Terapia de leucemia mielocìtica crÈnica
GEP19991514B (en) Method for Treatment with Interferon
EP1311286A4 (en) TREATMENT OF HEPATITIS C WITH THYMOSIN AND PEG-INTERFERON